Lomatin

Lomatin

SCHEMBL6273711

CC1(C)Oc2ccc3ccc(=O)oc3c2CC1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 12/20 1.00
▸ ALDH1A1 P00352 10/20 1.00
▸ HPGD P15428 9/20 1.00
▸ CYP3A4 P08684 3/20 1.00
▸ HSD17B10 Q99714 3/20 1.00
▸ MAPT P10636 3/20 1.00
▸ L3MBTL1 Q9Y468 1/20 0.60
▸ GAA P10253 5/20 0.56
▸ MGAM O43451 1/20 0.56
▸ SI P14410 1/20 0.56
▸ PTPN1 P18031 1/20 0.56
▸ ACHE P22303 1/20 0.56
▸ MGAM2 Q2M2H8 1/20 0.56
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ TSHR P16473 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.52
▸ RCE1 Q9Y256 1/20 0.47
▸ ABCB1 P08183 2/20 0.46
▸ LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(+)-Lomatin SCHEMBL29707947 1.00 KDM4E (1.00) KDM4EALDH1A1HPGDCYP3A4HSD17B10
SCHEMBL31349688 0.82 KDM4E (0.81) KDM4EALDH1A1HPGDCYP3A4HSD17B10
SCHEMBL29707867 0.79 KDM4E (0.76) KDM4EALDH1A1HPGDCYP3A4HSD17B10
SCHEMBL15444379 0.79 KDM4E (0.65) KDM4EALDH1A1HPGDCYP3A4HSD17B10
Jatamansin SCHEMBL30634819 0.77 KDM4E (1.00) KDM4EALDH1A1HPGDCYP3A4HSD17B10
Jatamansin SCHEMBL29385603 0.77 KDM4E (1.00) KDM4EALDH1A1HPGDCYP3A4HSD17B10
Jatamansin SCHEMBL14523891 0.77 KDM4E (1.00) KDM4EALDH1A1HPGDCYP3A4HSD17B10
Jatamansin SCHEMBL12062120 0.77 KDM4E (1.00) KDM4EALDH1A1HPGDCYP3A4HSD17B10
SCHEMBL29624043 0.75 L3MBTL1 (1.00) KDM4EALDH1A1HPGDCYP3A4HSD17B10
SCHEMBL4743847 0.75 L3MBTL1 (1.00) KDM4EALDH1A1HPGDCYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005105124-A1 PHARMACEUTICAL COMPOSITION COMPRISING THE PLANT COLEONEMA PHYTO MED HERBAL PRODUCTS (PROPRIETARY) LIMITED (ZA) 2005-11-10 — — WO claimed
US-8772252-B2 Coumarin compounds as melanogenesis modifiers and uses thereof NEW YORK UNIVERSITY (US) 2014-07-08 — — US disclosed
US-8772252-B2 Coumarin compounds as melanogenesis modifiers and uses thereof NEW YORK UNIVERSITY (US) 2014-07-08 — — US disclosed
US-8563754-B2 Compounds, compositions and methods for preventing skin darkening NEW YORK UNIVERSITY (US) 2013-10-22 — — US disclosed
US-8563754-B2 Compounds, compositions and methods for preventing skin darkening NEW YORK UNIVERSITY (US) 2013-10-22 — — US disclosed
US-20120220545-A1 COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF NEW YORK UNIVERSITY 2012-08-30 — — US disclosed
US-20120220545-A1 COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF NEW YORK UNIVERSITY 2012-08-30 — — US disclosed
WO-2011094016-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING NEW YORK UNIVERSITY (US) 2011-08-04 — — WO disclosed
US-20110190229-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING NEW YORK UNIVERSITY 2011-08-04 — — US disclosed
US-20110190229-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING NEW YORK UNIVERSITY 2011-08-04 — — US disclosed
WO-2005105124-A1 PHARMACEUTICAL COMPOSITION COMPRISING THE PLANT COLEONEMA PHYTO MED HERBAL PRODUCTS (PROPRIETARY) LIMITED (ZA) 2005-11-10 — — WO disclosed
WO-2005105124-A1 PHARMACEUTICAL COMPOSITION COMPRISING THE PLANT COLEONEMA PHYTO MED HERBAL PRODUCTS (PROPRIETARY) LIMITED (ZA) 2005-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220545-A1 COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF TYR, MC1R, MITF KDM4E 79/4885ALDH1A1 246/4885HPGD 2055/4885
US-20110190229-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING TYR, MC1R, MITF KDM4E 274/4885ALDH1A1 397/4885HPGD 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback